CARING PROGRESSIVE DYNAMIC TISSUE REGENIX GROUP PLC ANNUAL REPORT AND ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2017 TISSUE REGENIX GROUP PLC ANNUAL REPORT AND ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2017 TISSUE REGENIX GROUP IS A PIONEERING INTERNATIONAL MEDICAL TECHNOLOGY COMPANY FOCUSING ON THE DEVELOPMENT OF REGENERATIVE PRODUCTS UTILISING OUR TWO PLATFORM TECHNOLOGIES DCELL TECHNOLOGY ADDRESSING SOFT TISSUE NEEDS AND CELLRIGHT S BIORINSE PROVIDING INDUCTIVE BONE ALLOGRAFTS. WE ARE HELPING TO TRANSFORM THE TREATMENT OF PATIENTS IN FOUR KEY AREAS BIOSURGERY ORTHOPAEDICS SPORTS MEDICINE SPINE DENTAL AND CARDIAC in pipeline Porcine X Human H BIOSURGERY CARDIAC ORTHOPAEDIC THICKER DERMIS NAVIGATING THE REPORT FOR FURTHER INFORMATION WITHIN THIS DOCUMENT AND RELEVANT PAGE NUMBERS SCAN THE QR CODE TO LEARN MORE ABOUT OUR dCELL TECHNOLOGY IN THIS SHORT VIDEO OR VISIT WWW TISSUEREGENIX COM MEDIA INNOVATIONS IN SOFT TISSUE REGENERATIVE MEDICAL TECHNOLOGY SCAN THE QR CODE TO LEARN MORE ABOUT CELLRIGHT TECHNOLOGIES IN THIS SHORT VIDEO OR VISIT WWW TISSUEREGENIX COM MEDIA HEALING SKELETAL DEFECTS THROUGH REGENERATIVE MEDICINE TICKER AIM TRX www tissueregenix com Who We Are OUR VISION To establish Tissue Regenix as a leader in the science and innovation of regenerative medicine and become clinicians partner of choice to meet growing clinical needs transform patient care and deliver favourable health economic outcomes. OUR STRENGTHS Two complementary proven regenerative medicine platforms addressing applications in both soft tissue and bone State of the art in house manufacturing capabilities in the UK Europe and North America Multiple development and commercialisation opportunities Experienced and dedicated management and scientific teams. dCELL TISSUE STRATEGY LEARN MORE ABOUT US OVERVIEW Highlights 01 Chairman s Statement 02 Corporate Structure 03 Who are CellRight Technologies. 04 What is Regenerative Medicine. 05 Complementary Platform Technologies 06 STRATEGIC REPORT CEO Operational Review 07 Our Strategy 10 DIVISIONAL OVERVIEW TRX BioSurgery 12 Orthopaedics and Dental 14 CellRight Technologies 15 Cardiac 16 GBM V 17 Financial Overview 18 Risks 19 Corporate Social Responsibility 21 GOVERNANCE Profile of the current directors 22 Governance Framework 24 Directors Remuneration Report 26 Directors Report 30 Statement of Directors Responsibilities 31 FINANCIALS Independent Auditor s Report to the members of Tissue Regenix Group plc 32 Consolidated Statement of Comprehensive Income 36 Consolidated Statement of Changes in Equity 37 Consolidated Statement of Financial Position 38 Consolidated Statement of Cash Flows 39 Notes to the Financial Statements 40 Company Statement of Changes in Equity 60 Company Statement of Financial Position 61 Company Statement of Cash Flows 62 Notes to the Company Information 63 Notice of Annual General Meeting 65 Directors and Officers IBC Highlights Z GROUP SALES INCREASED TO 5 233K DermaPure sales under TRX BioSurgery increased by 46 to 1 932K Increased sales from GBM V to 1 135K Four months of CellRight contribution of 2 166K. Z GROUP LOSS FOR THE YEAR OF 9 4M Improvement from 9 9m 11 months to December 2016 Investment into research and development continues. Z COMPLETED ACQUISITION OF CELLRIGHT TECHNOLOGIES IN AUGUST 2017 Successfully raised 40m gross of costs through an equity fundraising Provides complementary regenerative technology platform and world class facility Operational integration on track with initial synergies recognised. Z POST PERIOD HIGHLIGHTS Strategic distribution agreements with ARMS Medical for DermaPure Long term distribution agreement signed with Arthrex Inc for CellRights BioRinse portfolio. I AM VERY PLEASED WITH THE PROGRESS THE GROUP HAS MADE DELIVERING AGAINST OUR STRATEGIC OBJECTIVES FOR THE YEAR FOR MORE INFORMATION SEE PAGE 02 OVERVIEW TISSUE REGENIX GROUP PLC ANNUAL REPORT AND ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2017 01 Our Business The Group has performed well against our strategic milestones for the year. The acquisition of CellRight Technologies is a transformative opportunity for the Group combining two innovative regenerative platforms with large addressable markets and synergistic growth opportunities. With the appointment of Steve Couldwell as CEO the Board is confident that it has the leadership in place to take the Company to the next stage and a comprehensive review of the development pipeline is ongoing. With our augmented established product portfolio generating a growing level of sales we have identified key development assets to focus our commercial resources behind and we are confident that following final product validation and transfer of manufacturing in house the newly focused strategy will drive significant shareholder returns. Financial Performance Overall Group performance The Group delivered revenues of 5 233K in the 12 months to 31 December 2017 a 263 increase when compared to the 11 month period to December 2016. Organic DermaPure sales grew 46 in the US to 1 932K and the commercial traction of the European controlled joint venture continued with increased revenues to 1 135K. Following the equity fundraising undertaken in August 2017 the Group has a robust cash position to fund the near term future of the enlarged Group and we maintain our expectation that the Group will be cash break even during 2020. Leadership In November 2017 we announced the appointment of Steve Couldwell as CEO of the Group. Steve succeeds Antony Odell who stepped down in October 2017 after nine years leading the Group. We would like to thank Antony for his leadership during the Group s early years. Steve has experience spanning over 25 years in the Medical Device space and a proven track record of delivering revenue and profit growth. He has had an extensive career including Smith Nephew and more recently Sanofi BioSurgery based in Boston Massachusetts. Having held senior commercial positions in both the US and Europe Steve has the necessary skill set to drive the next stages of the Group s commercial strategy required to deliver shareholder returns. Following the resignation of Paul Devlin on 30 November we have appointed an interim CFO and initiated a search for a permanent candidate. Our People The Board and I would like to extend our thanks to our employees and partners especially throughout this year of significant change. With the integration of CellRight Technologies we welcomed a new team in the US led by CEO Jesus Hernandez and the 